eisai-europe-limited

eisai-europe-limited

Partenaire YouScribe

84 publication(s)
2 623 consultation(s)
Toutes ses publications
Zonegran® (zonisamida), bien tolerado en el ... eisai-europe-limited

Zonegran® (zonisamida), bien tolerado enZonegran® (zonisamida), bien tolerado en el tratamiento prolongado de los niños que

Zonegran® (zonisamide) chez les enfants ... eisai-europe-limited

Zonegran® (zonisamide) chez les enfantsZonegran® (zonisamide) chez les enfants souffrant de crises d'epilepsie partielles :

Zonegran® (Zonisamide) Well Tolerated in ... eisai-europe-limited

Zonegran® (Zonisamide) Well Tolerated inZonegran® (Zonisamide) Well Tolerated in Long-term Treatment of Children with Partial

Halaven® (Eribulin) Now Commercially Available ... eisai-europe-limited

Halaven® (Eribulin) Now CommerciallyHalaven® (Eribulin) Now Commercially Available in Lebanon for the Treatment of Metastatic

Eisai to Collaborate with Liverpool School of ... eisai-europe-limited

Eisai to Collaborate with Liverpool SchoolEisai to Collaborate with Liverpool School of Tropical Medicine and University of

Zonegran® (Zonisamide) Approved for Use in ... eisai-europe-limited

Zonegran® (Zonisamide) Approved forZonegran® (Zonisamide) Approved for Use in Children and Adolescents by Scottish Medicines

El Ministerio de Sanidad español autoriza la ... eisai-europe-limited

El Ministerio de Sanidad español autorizaEl Ministerio de Sanidad español autoriza la financiación de Zonegran® (zonisamida)

Epilepsy Treatment Zonegran® (Zonisamide) ... eisai-europe-limited

Epilepsy Treatment Zonegran®Epilepsy Treatment Zonegran® (Zonisamide) Receives Reimbursement in Spain as Monotherapy for Adults

Feu vert en Espagne pour le remboursement de ... eisai-europe-limited

Feu vert en Espagne pour leFeu vert en Espagne pour le remboursement de Zonegran® (zonisamide) dans deux nouvelles indications

Fycompa® (Perampanel) to be Resubmitted Early ... eisai-europe-limited

Fycompa® (Perampanel) to beFycompa® (Perampanel) to be Resubmitted Early to German Federal Joint Committee (G-BA) for

L'essai select de phase III du lenvatinib ... eisai-europe-limited

L'essai select de phase III du lenvatinibL'essai select de phase III du lenvatinib satisfait à son critère principal:

El ensayo SELECT de fase III de lenvatinib ... eisai-europe-limited

El ensayo SELECT de fase III de lenvatinibEl ensayo SELECT de fase III de lenvatinib cumple con el criterio principal de

Once-daily Epilepsy Treatment Zebinix® ... eisai-europe-limited

Once-daily Epilepsy Treatment Zebinix®Once-daily Epilepsy Treatment Zebinix® (Eslicarbazepine Acetate) Now Available with Full

Phase III Select Trial of Lenvatinib Meets ... eisai-europe-limited

Phase III Select Trial of Lenvatinib MeetsPhase III Select Trial of Lenvatinib Meets Primary Endpoint of Improved Progression

Zonegran® (zonisamide) Reimbursed in ... eisai-europe-limited

Zonegran® (zonisamide) Reimbursed inZonegran® (zonisamide) Reimbursed in Switzerland as Monotherapy Treatment for Adults With

New First-in-class Epilepsy Treatment Fycompa® ... eisai-europe-limited

New First-in-class Epilepsy TreatmentNew First-in-class Epilepsy Treatment Fycompa® (perampanel) Launches in Spain PR Newswire

Lanzamiento en España de Fycompa® (perampanel), ... eisai-europe-limited

Lanzamiento en España de Fycompa®Lanzamiento en España de Fycompa® (perampanel), un nuevo tratamiento primero en su clase para

European Commission Grants Orphan Drug Status ... eisai-europe-limited

European Commission Grants OrphanEuropean Commission Grants Orphan Drug Status to Eisai's Amatuximab for the Treatment of

Life-extending Metastatic Breast Cancer ... eisai-europe-limited

Life-extending Metastatic Breast CancerLife-extending Metastatic Breast Cancer Treatment Now Available in the Republic of

Innovative Metastatic Breast Cancer Treatment ... eisai-europe-limited

Innovative Metastatic Breast CancerInnovative Metastatic Breast Cancer Treatment Halaven® (Eribulin) Recieves Reimbursement

Inovelon® (Rufinamide) Oral Suspension ... eisai-europe-limited

Inovelon® (Rufinamide) Oral SuspensionInovelon® (Rufinamide) Oral Suspension Formulation Launched in Portugal PR Newswire

Eisai's Named Patient Access Programme for ... eisai-europe-limited

Eisai's Named Patient Access ProgrammeEisai's Named Patient Access Programme for Fycompa® (perampanel) Available from 1 January

Eisai anuncia nueva colaboración con Esteve ... eisai-europe-limited

Eisai anuncia nueva colaboración conEisai anuncia nueva colaboración con Esteve para la promoción del fármaco contra la

Eisai Announces New Partnership with Esteve to ... eisai-europe-limited

Eisai Announces New Partnership withEisai Announces New Partnership with Esteve to Promote Anti-epilepsy Drug Zonegran®